Experimental treatment shows promise in treating rare form of blindness

Dutch drugmaker ProQR Therapeutics has reported promising results from an early stage trial targeting children with a rare form of blindness.

According to the company, the experimental drug, QR-110, improved vision in 60 percent of patients enrolled in the small study.

There are currently about 2,000 people in the U.S. and Europe with the condition called Leber’s congenital amaurosis 10, an inherited disease that appears in birth and leads to severe visual impairment.

There are currently no approved treatments for the condition. Analysts estimate that the market to treat the disease is worth about $700 million.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.